Please login to the form below

Not currently logged in

AP Pharma appoints Dendreon’s Jesse Hollingsworth to lead sales

Joins as company prepares to advance APF350 to treat side effects of chemotherapy

Jesse Hollingsworth has left Dendreon to join AP Pharma as VP of sales.

The appointment comes as AP Pharma prepares to advance its lead product APF350, which is intended for the prevention of acute- and delayed-onset chemotherapy-induced nausea and vomiting.

“Over the past several months, AP Pharma has been focused on recruiting key additions to our management team, and Jesse's experience in oncology sales will provide insights into the sales progamme for ... APF350,” said Robert Rosen, AP Pharma's chief commercial officer.

This experience includes Hollingsworth's time as senior director of group purchasing organisation and trade strategy at Dendreon, which developed the prostate cancer vaccine Provenge.

Prior to this role, Hollingsworth was senior director of strategic business development and marketing at ION Solutions.

This was preceded by a period as marketing director for the oncology business unit of Amgen, where he worked on such products as Neulasta, Neupogen and Vectibix.

5th March 2013

From: Sales



Featured jobs

Subscribe to our email news alerts


Add my company
Random42 Scientific Communication

Random42 is the world's leading medical animation company. Over the past 25 years we have produced core digital assets for...

Latest intelligence

Waking the sleeping giant
The lights are coming on for healthcare delivery in Africa...
How to get rep buy-in for multi-channel
How do you manage a team who may be resistant to change?...
Blog: Digital therapeutics: within our reach?
Digital therapeutics is a hot topic right now. By using digital technology to manage, treat or even prevent chronic conditions, digital therapeutics is promising to revolutionise healthcare. But is this...